Skin & hair · Prescription only
GLOW
A compounded blend of GHK-Cu, BPC-157, and TB-500, available after a licensed-provider evaluation.
Treatment length is confirmed at checkout after your provider approves treatment.
Beginning treatment does not create a prescription. A US-licensed provider reviews your intake first, and an order is only filled if they determine treatment is appropriate for you.
Treatment details
- Medication
- GLOW
- Category
- Skin & hair
- Access
- Available after a licensed-provider evaluation
- Fulfillment
- Compounded by a US-licensed compounding pharmacy
- FDA status
- Compounded — not FDA-approved
- Shipping
- Discreet, United States only
$269.00 is a placeholder price pending final confirmation. Van Peptides does not compound, manufacture, or dispense medication itself.
What it is
GLOW is Van Peptides’ name for a compounded blend of three peptides studied, individually, in the skin and soft-tissue literature: GHK-Cu, a naturally occurring copper tripeptide associated with collagen synthesis and skin remodeling (Pickart & Margolina review, PMID 18644225); BPC-157, a synthetic pentadecapeptide studied in preclinical models for tissue-repair signaling (Current Reviews in Musculoskeletal Medicine, 2025); and TB-500, derived from thymosin beta-4 and studied for its role in cell migration and wound healing (Sosne et al., 1999, PMID 10469335). Outcomes are individual, and no published study has evaluated this three-peptide combination as a single blend.
GLOW is available after a licensed-provider evaluation. Van Peptides does not compound or dispense it: any prescription that follows an evaluation is compounded through a US-licensed compounding pharmacy.
Van Peptides connects patients with an independent network of US-licensed providers who determine whether this blend is appropriate for you. We do not diagnose, prescribe, or dispense, and we do not employ the providers or the compounding pharmacy.
What the literature has explored
Each component of GLOW has its own separate literature. GHK-Cu has controlled human-skin studies describing improved elasticity, firmness, and reduced appearance of fine lines and photodamage, alongside earlier rodent wound-healing work showing increased connective tissue accumulation (Maquart et al., 1993, PMID 8227353; Pickart & Margolina, PMID 18644225). BPC-157’s supporting data is largely preclinical, centered on angiogenesis and fibroblast activity in animal tendon and tissue-injury models (Current Reviews in Musculoskeletal Medicine, 2025). TB-500’s parent molecule, thymosin beta-4, has animal wound-healing data showing faster reepithelialization and increased collagen deposition, with a 2026 scoping review noting that direct human evidence for the synthetic TB-500 fragment specifically remains limited.
No published study has evaluated these three peptides combined as a single blend, so any expectation about GLOW as a whole is an extrapolation from three separate bodies of single-compound research, not a finding on its own. Outcomes are individual, and that gap between individual-ingredient data and combination-product expectations is exactly the kind of question a licensed provider should walk through with you.
We think it is more honest to say that plainly than to imply the blend has been studied as a unit when it has not.
How the telehealth path works
- Complete a short online intake.
- A US-licensed provider reviews your history and speaks with you if appropriate.
- If clinically appropriate, a prescription is issued and routed to a US-licensed compounding pharmacy.
- The medication ships discreetly in the US, with dispensing instructions from the pharmacy.
Van Peptides is a technology platform. It does not diagnose, prescribe, compound, or dispense. Each step above is carried out by an independent US-licensed provider or a US-licensed compounding pharmacy.
Common questions
What is GLOW?
It is Van Peptides’ name for a compounded blend of GHK-Cu, BPC-157, and TB-500, three peptides studied individually in the skin and soft-tissue literature.
Who is a candidate?
A US-licensed provider determines candidacy after reviewing your intake and history; it is available after a licensed-provider evaluation.
Is it FDA approved?
No. None of GHK-Cu, BPC-157, or TB-500 is FDA approved individually or combined, and no FDA-approved brand-name version of this blend exists.
How is it dispensed?
If prescribed, GLOW is compounded through a US-licensed compounding pharmacy and shipped to you.
What does it cost?
Placeholder plan pricing is $149 monthly, $399 for a three-month plan, and $749 for a six-month plan. Final pricing will be confirmed before this page goes live.
How is my privacy protected?
Your intake and health information are handled under our HIPAA Notice of Privacy Practices.
What if it isn’t right for me?
If a provider determines GLOW is not appropriate for you, they will discuss individual components or other options as part of your evaluation.